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Abstract
Background: Despite a substantial burden of non-bacteraemic methicillin resistant Staphylococcus aureus (MRSA) disease,
most MRSA surveillance schemes are based on bacteraemias. Using bacteraemia as an outcome, trends at hospital level are
difficult to discern, due to random variation. We investigated rates of nosocomial bacteraemic and non-bacteraemic MRSA
infection as surveillance outcomes.
Methods and Findings: We used microbiology and patient administration system data from an Oxford hospital to estimate
monthly rates of first nosocomial MRSA bacteraemia, and nosocomial MRSA isolation from blood/respiratory/sterile site
specimens (‘‘sterile sites’’) or all clinical samples (screens excluded) in all patients admitted from the community for at least
2 days between April 1998 and June 2006. During this period there were 441 nosocomial MRSA bacteraemias, 1464 MRSA
isolations from sterile sites, and 3450 isolations from clinical specimens (8% blood, 15% sterile site, 10% respiratory, 59%
surface swabs, 8% urine) in over 2.6 million patient-days. The ratio of bacteraemias to sterile site and all clinical isolations
was similar over this period (around 3 and 8-fold lower respectively), during which rates of nosocomial MRSA bacteraemia
increased by 27% per year to July 2003 before decreasing by 18% per year thereafter (heterogeneity p,0.001). Trends in
sterile site and all clinical isolations were similar. Notably, a change in rate of all clinical MRSA isolations in December 2002
could first be detected with conventional statistical significance by August 2003 (p=0.03). In contrast, when monitoring
MRSA bacteraemia, identification of probable changes in trend took longer, first achieving p,0.05 in July 2004.
Conclusions: MRSA isolation from all sites of suspected infection, including bacteraemic and non-bacteraemic isolation, is a
potential new surveillance method for MRSA control. It occurs about 8 times more frequently than bacteraemia, allowing
robust statistical determination of changing rates over substantially shorter times or smaller areas than using bacteraemia as
an outcome.
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Introduction
Staphylococcus aureus is responsible for a substantial burden of
nosocomial disease; for example, being named in 8% of hospital
discharge diagnoses in a recent study in the United States[1]. In
the UK, which has had a large outbreak of two clones of
methicillin-resistant S. aureus (MRSA) for the last fifteen years,
MRSA now accounts for 37% of S. aureus blood stream isolates[2],
with evidence that it has added to the burden of disease caused by
methicillin sensitive S. aureus[3]. Consequently, reduction in
MRSA disease burden has become a key UK government priority,
with a much publicised target of a 50% reduction in MRSA
bacteraemia by 2008. Despite this, there have been very few
rigorous evaluations of how best to control MRSA[4], with
optimal metrics for examining the effect of interventions little
studied. MRSA bacteraemia is a serious outcome, amendable to
passive surveillance; however, it is recognised that monitoring
using bacteraemia rates necessitates long periods of follow-up to
determine whether infection control interventions have had an
effect in a hospital or hospital subunit[5].
Nosocomial isolation of MRSA from sites other than blood is
also of clinical significance, and can arise in two settings: one in
which the patient is clinically infected, and the other in which they
are not and are carriers of the organism. Carriage of Staphylococcus
aureus is a well-recognised precedent of infection with the same
strain[6], and multiple studies show MRSA isolation from diverse
sites, including ulcers, is associated with high risk of subsequent
clinical infection[7–9]. Isolation of S. aureus is common with
ventilator associated pneumonia[10] and surgical site infec-
tions[11]: for both, MRSA increases morbidity, hospital stay and
costs relative to methicillin sensitive strains[12–15].
Here, we describe nosocomial MRSA bacteraemia and isolations
from other clinical samples in a large teaching hospital over a
10 year period, demonstrating that changes over time are very
similar, but that non-bacteraemic isolations are about 8 times more
common. We further investigate whether, using MRSA isolation
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rapid and precise estimates of trends in nosocomial MRSA isolation
can be formed than by the use of bacteraemic isolates alone.
Methods
Participants
Our study included data from the John Radcliffe Hospital, the
Radcliffe Infirmary, the Churchill Hospital and the Horton General
Hospital (the Oxford Radcliffe Trust, ORH, UK), which offer the
majority of specialist regional services plus acute clinical and
bacteriology services to about 600,000 people. Admissions to other
much smaller hospitals in the area (including a specialist orthopaedic
hospital, psychiatric hospitals, and several community hospitals)
were not included. Microbiological processing used standard
techniques, as recommended by the standard operating procedures
of the Health Protection Agency. Patient admissions, excluding
outpatients, between 1 January 1997 (1 January 1999 for Horton)
and 31 July 2006 were anonymously linked to information on
microbiology isolates from 1 January 1995 and 31 July 2006, using
previouslydescribed methods[3].Here, we restrictanalysis to1 April
1998 to 30 June 2006 to ensure that exposure to MRSA before
admission can be estimated for at least 3 years in all cases, and
discharge status is known on almost all the cohort.
Outcomes
The outcomes considered were
N nosocomial isolations of MRSA[3], defined as isolations from
patients admitted to ORH for at least the previous 2 days from
N blood cultures
N blood cultures and all other samples taken due to clinical
suspicion of infection (non-screening ‘‘clinical samples’’),
except for vascular line tip cultures, which we excluded
because of their relationship to blood cultures.
N blood cultures and clinical samples only from respiratory and
normally sterile sites taken under aseptic technique, such
ascites, joint aspirates, cerebrospinal fluid, pre-prosthetic
material, and collections of pus.
Following the principle that an outcome should be counted if
either the event of interest or a more serious event has occurred,
we compared MRSA isolation from blood cultures with isolation
from both blood cultures and other specimens (rather than other
specimens alone), analogous to, for example, comparing time to
death and time to myocardial infarction or death.
For blood, blood/respiratory/sterile site and all clinical isolates,
we analysed those samples:
N taken during the period 1 April 1998 and 30 June 2006
N when there was no positive MRSA isolation from that group of
sites within the previous 14 days, analogous to the process
recommended for bacteraemia reporting[2]
N which were the first such positive isolation per admission, to
focus on new infections rather than repeat isolations which
could be influenced by persistent, unresolved infected sites
(such as fistulae and wound drains).
We excluded the following admissions from analysis:
N those with MRSA isolated from the group of sites within the
first 2 days of admission, since we wished to study nosocomial
isolation
N inter-hospital transfers, since their total prior hospital stay was
unknown.
Statistical analysis
We used Poisson regression to estimate the incidence of
nosocomial MRSA infection, including as denominator one day for
every part of a calendar day spent in ORH hospitals .2d a y sa f t e r
admission (providing the patient had not had an outcome within
2 days of this admission) up to the earliest of discharge, death or the
MRSA outcome; and numerator whether or not MRSA was isolated
from a sample taken on that day for each patient. Patients could
contribute more than one nosocomial isolation to analysis if these
occurred in different admissions. A succession of simple two trend
models were fitted to explore changes in rate over calendar time, and
the model minimising the Akaike Information Criterion (AIC[16])
presented,providingthistwo-slopemodelwasa significantlybetterfit
than a single trend model (similar results obtained using negative
binomial regression allowing extra variability in monthly rates, and
similar relationship between outcomes using three trend models). All
analyses were unadjusted reflecting our objective of evaluating
MRSA isolations as a surveillance measure. To investigate the ability
toreliablydetectsimilartrendstothoseweobservedinORHinother
hospitals, we simulated genuine reductions in different event rates
across two equal periods of observation of varying lengths, and
related the probability of detecting this reduction as being statistically
significant to common sizes of hopsital/division/speciality. Stata 9.2
was used for all analyses.
ETHICS APPROVAL
Not required as linkage was anonymous; approval for the study
obtained from the Caldicott guardian as with our previous studies.
Results
Repeated isolation of MRSA from different clinical samples
from a single patient is common; to estimate the number of
infections, we determined the first clinical isolation (FCI) of MRSA
for each patient admitted between 1 April 1998 and 1 July 2006,
initially considering all clinical samples (excluding screens). 8% of
FCIs .2 days after admission were from blood, with 15% from
other normally sterile locations (including pus and periprosthetic
samples), 10% from respiratory samples, 59% from surface
cultures (e.g. ulcers and wounds), and the remaining 8% from
urine specimens, a total of 3450 FCIs (Table 1). If MRSA
isolations from surface cultures and urine samples (whose clinical
significance can be difficult to assess in some individuals) are
excluded, over the same period there were 1464 FCIs. If only
blood cultures were included, there were 441 FCIs, with
bacteraemia (positive blood culture) being the first nosocomial
MRSA isolation during the admission in only 269 cases.
Notably, the characteristics of patients with bacteraemia,
blood/respiratory/sterile site and any clinical MRSA isolation
had many similarities (Table 1). For example, median ages were
similar (73, 72 and 74 years respectively), as were the durations
that the patients had been in hospital prior to the current isolation
(median 16, 14 and 15 days respectively). While large numbers of
non-bacteraemic isolations provide enough statistical power to
show these differences may not be due to chance alone (Table 1),
they are unlikely to be important clinically. The main difference
was between the proportions of patients who had had MRSA
isolated from any sample, clinical or MRSA screen, taken in or
outside of hospital before this admission (12% for bacteraemia,
19% for blood/respiratory/sterile site isolation, and 20% for any
clinical isolation, p=0.001). There were also small differences in
Monitoring MRSA Control
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13 days respectively, p=0.02). We also observed the expected
small variations by admission speciality (p=0.002), with propor-
tionately more bacteraemias in line-intensive specialities of
haematology, oncology, and nephrology.
Figure 1 (top panels) shows the monthly nosocomial MRSA
incidence per 10,000 patient-days in ORH over calendar time.
Inspection suggests that incidence of both MRSA bacteraemia and
MRSA isolation from other clinical samples increased then
declined, while their ratio changed little.
Poisson regression was used to assess the significance of these
trends. We found that incidence of nosocomial MRSA bacterae-
mia increased by 27% per year to July 2003 (p,0.001, Table 2,
solid line Figure 1 top panels) before declining by 18% per year
Table 1. Comparison of characteristics of first MRSA isolation from various clinical sites .2 days after admission to Oxford
Hospitals, 1998–2006
Bacteraemia
N=441
Blood,
respiratory,
sterile site
N=1464
All clinical
isolates
N=3450 Global
(1)
vs
(2)
(1)
vs
(3)
(2)
vs
(3)
Factor Subcategory
n (%) or
median
(IQR)
n (%) or
median
(IQR)
n (%) or
median
(IQR) p* p* p* p*
Site** blood 441 (100%) 346 (24%) 269 (8%) - - - -
sterile site 729 (50%) 527 (15%)
respiratory 389 (27%) 352 (10%)
surface/genital swab 2031 (59%)
urine 271 (8%)
Financial year of positive 1998 20 (5%) 91 (6%) 204 (6%) 0.05 0.68 0.14 0.04
1999 32 (8%) 115 (8%) 248 (7%)
2000 44 (10%) 153 (11%) 365 (11%)
2001 54 (13%) 196 (14%) 401 (12%)
2002 74 (18%) 248 (17%) 523 (16%)
2003 92 (22%) 258 (18%) 587 (18%)
2004 59 (14%) 187 (13%) 526 (16%)
2005 45 (11%) 170 (12%) 489 (15%)
2006{ 21 46 107
Days from admission to positive 16 (7–31) 14 (7–28) 15 (8–30) 0.04 0.07 0.67 0.02
Sex female 167 (38%) 569 (39%) 1471 (43%) 0.02 0.71 0.06 0.01
Age at admission (years) 73 (63–81) 72 (58–80) 74 (60–82) 0.0003 0.05 0.59 0.0001
Any previous MRSA{ screening or clinical sample 55 (12%) 275 (19%) 684 (20%) 0.001 0.002 ,0.0001 0.40
screening sample only 16 (4%) 39 (3%) 82 (2%)
clinical sample only 18 (4%) 106 (7%) 266 (8%)
clinical and screen 21 (5%) 130 (9%) 336 (10%)
Never previously admitted to ORH 120 (27%) 401 (27%) 861 (25%) 0.16 0.94 0.30 0.07
Last discharge from ORH (days before
this admission)
56 (15–290) 59 (17–272) 69 (18–314) 0.22 0.66 0.20 0.16
Number of prior ORH admissions 2 (0–4) 2 (0–4) 2 (1–4) 0.04 0.62 0.06 0.04
Days in ORH prior to this admission 10 (0–33) 11 (0–37) 13 (1–41) 0.02 0.37 0.03 0.04
Admission speciality trauma/A&E/ortho/cardio 34 (8%) 172 (12%) 352 (10%) 0.002 0.004 0.006 0.05
specialityobs/gynae/paeds/ENT 16 (4%) 88 (6%) 219 (6%)
haemat/onc/nephr 29 (7%) 50 (3%) 145 (4%)
surgery 162 (37%) 511 (35%) 1086 (31%)
medicine: elective 5 (1%) 20 (1%) 55 (2%)
medicine: emergency 195 (44%) 623 (43%) 1593 (46%)
Non-medical emergency 145 (33%) 489 (33%) 1043 (30%) 0.07 0.84 0.25 0.03
*univariable p values from chi-squared or Kruskal-Wallis/ranksum tests for categorical and continuous variables respectively.
**first MRSA isolation from specified samples this admission (predominant site according to order above when MRSA isolated from multiple types of specimens on the
same day).
{3 months April to June 2006: percentages are of complete financial years only.
{any sample tested at ORH from 1 January 1995 onwards, during or outside of an ORH admission, but strictly before the current admission
Note:excluding repeated positive isolations within a single admission.
doi:10.1371/journal.pone.0002378.t001
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ry/sterile site and all clinical isolations similarly increased
significantly (by 25% and 23% per year to November/December
2002 respectively) and then declined significantly (by 13% and 5%
per year respectively) (all p,0.01), although their incidence was a
median 3.3 and 8.0-fold higher than bacteraemia alone (Figure 1
second row of panels). While MRSA isolation declined significantly
for all outcomes, using a multivariate Poisson model, estimates of the
decline in all clinical MRSA isolations were slightly smaller than
declines in bacteraemia (13% smaller per year [95% CI 1–26%
smaller] p=0.02) but more similar to declines in blood/respiratory/
sterile site (4% smaller per year [15% smaller-5% larger] p=0.39)
(with similar results estimating declines after December 2002 for all
outcomes). Analysing ratios of the incidence of bacteraemia/
respiratory/sterile site or all clinical isolations to bacteraemia, we
found no significant time trends. Similar results were obtained
excluding patients with any MRSA positive clinical or screening
samplebeforethecurrentadmission(leaving386bacteraemias,1189
bacteraemia/respiratory/sterile site and 2776 clinical samples in
total), although the most likely time for the reduction in MRSA
bacteraemias to have started was slightly earlier (December 2002
compared with July 2003 in all patients). Similar results were also
obtained comparing non-overlapping groups of bacteraemic versus
non-bacteraemic MRSA isolations. In summary, multiple methods
of analysis suggest that changes in incidence of first clinical MRSA
isolation are similar whether blood cultures, all clinical samples, or a
subset of all clinical samples are studied.
Given recent intensive infection control initiatives, a key
question is when the increase in MRSA incidence actually
reversed. Studying our hospital Trust from 1998–2006, the most
likely time that the reduction in MRSA incidence started varied a
little with outcome (July 2003, November 2002 and December
2002 respectively), but the range of times that could not be
distinguished statistically from this most likely time overlapped
substantially (Table 2, Figure 1 top panels). This illustrates the
difficulty in determining exactly when changes in incidence have
occurred given natural random (stochastic) variation, even in large
Trusts. Notably, there was much greater uncertainty in when the
change in MRSA bacteraemia might have occurred (22 months
from March 2002 to January 2004), compared to other outcomes
(10 months).
Continuous review and monthly reporting of MRSA bacterae-
mia is a mandatory requirement in the UK. We considered to
what extent the three MRSA outcome measures described above
(bacteraemia, isolation from blood/respiratory/sterile sites, and all
clinical isolates) could help an infection control team decide
whether and how MRSA incidence was changing, by plotting for
data up to and including each month from April 2000 through
June 2006, the best current estimate of the relative annual rate of
increase/decrease in MRSA incidence classified by the statistical
Figure 1. MRSA INCIDENCE OVER TIME. TOP PANELS: Monthly nosocomial MRSA incidence, and change in relative rates from blood cultures, the
combination of bacteraemia, respiratory and sterile site samples, and all clinical samples. MIDDLE PANELS: estimates of relative annual rate of increase
or decrease in incidence, calculated each month from April 2000 to June 2006. LOWER PANELS: the point at which changes in rate were most likely to
have occurred, and when they could have been confidently detected by an infection control team monitoring trends.
doi:10.1371/journal.pone.0002378.g001
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mid-2001 there was weak evidence that MRSA incidence was
going up for each outcome. From mid-2001 to mid-2003, it was
clear that MRSA incidence from all clinical and blood/
respiratory/sterile site samples was increasing significantly, but
the evidence for increasing incidence of nosocomial MRSA
bacteraemia much less strong (particularly in 2002). Through the
second-half of 2003 it became clear that MRSA incidence from all
clinical and blood/respiratory/sterile site samples was now declining
significantly compared to their earlier increase. From mid-2004
onwards, there was also statistical evidence for a decline in MRSA
bacteraemias, but the confidence intervals around the estimated
reduction were far wider, and drift upwards, with a short period
(July/August 2004) with only 3 and 1 nosocomial bacteraemias
respectively having large influence. Considering when the increases
inMRSAincidencewerefirstconsistentlyestimated tohavereversed
(Figure 1, bottom panels), we found that the decline in incidence of
all clinicalnosocomialMRSAfromDecember2002 wasidentified at
the 10% significance level in October 2003, compared to February
2004 for blood/respiratory/sterile site samples. Changes with
greater statistical certainty (p,0.1) and in bacteraemias took longer
to detect. In summary, throughout the period studied, use of blood
culture alone as a measure afforded more variable estimates of
current trend than other measures, and detected changes in
incidence later.
Oxford Radcliffe Trust is one of the largest Acute Hospital Trusts
in the UK. An average Acute Hospital Trust is about half the size,
and a small Trust on the 25th centile of the UK distribution is about
35% the size[2]. We therefore considered how long a period of
observation would be needed to reliably (.90% probability/power)
detect the required 50% or a more modest 25% reduction in MRSA
incidence in varying sizes of hospital populations, from a baseline
incidence similar to that we observed for bacteraemias (2/10000
patient days), bacteraemia/respiratory/sterile site (8/10000 patient
days) and all clinical specimens (16/10000 patient days), under a
simple Poisson assumption (Figure 2). With the least common
outcome (blood cultures), periods of ,12 months were needed even
in the largest hospitals to reliably detect 50% reductions, and periods
of 2 or more years were needed to provide the same power in smaller
clinicalunits.Incontrast,withthe mostcommonoutcome(allclinical
samples), 50% reductions could be reliably detected in ,12 months
even in areas the size of speciality groups, and smaller changes of
25% could be detected in 6–12 months in larger hospitals.
Discussion
Here we show that whilst trends over time in nosocomial
bacteraemic and non-bacteraemic isolates of MRSA are similar in
a large UK Acute Hospital Trust over a 10 year period, non-
bacteraemic clinical isolates are about 8-fold more frequent, with
their ratio relatively constant. For reasons which are not
investigated here, incidence of both outcomes declined progres-
sively from early 2003, offering the opportunity to assess the ability
of isolations from different types of clinical specimen to monitor
changes in MRSA. Similar patient characteristics and time trends
suggest that similar populations are likely to be at risk for both
bacteraemic and non-bacteraemic isolation, with bacteraemia an
indicator of the most severe infection across a spectrum rather
than having different epidemiology. Indeed, there is extensive
overlap between these groups, with two thirds of patients with
bacteraemia also having MRSA isolated from a non-blood source
during the same admission, around half of these isolations being
prior to the bacteraemia (rather than prompted by a positive blood
culture). Due to the vastly different incidence between bacteraemia
and non-bacteraemic isolation, all clinical isolations was a more
sensitive measure for detecting changes in MRSA rates in our
Trust over 1998–2006 than bacteraemia alone.
What are the limitations of the proposed surveillance measure,
given that, as is likely, practical issues of data collection and
computation can be readily addressed by appropriate information
Table 2. Changes in rates of first MRSA isolation .2 days after admission to Oxford Hospitals from various clinical sites over 1998–
2006
Bacteraemia
Blood, respiratory,
sterile site All clinical isolates
Positive isolations 441 1464 3450
- mean isolations per month in 1999 2.3 9.4 19.4
- mean isolations per month in 2002 5.8 20.8 42.7
- mean isolations per month in 2005 3.5 13.2 40.6
Patient days at risk from .2 days after admission to the earliest of
discharge, death or MRSA isolation
2,676,180 2,654,119 2,617,870
Most likely time that trend in rates changes (‘‘changepoint’’)* July 2003 November 2002 December 2002
Fold change in isolation rate per year to this changepoint (HR (95%
CI) p)
1.27 (1.18–1.37),0.001 1.25 (1.19–1.31),0.001 1.23 (1.19–1.27),0.001
Fold change in isolation rate per year subsequently (HR (95% CI) p) 0.82 (0.72–0.93) 0.002 0.87 (0.82–0.92),0.001 0.95 (0.92–0.98) 0.008
Heterogeneity p value het p,0.001 het p,0.001 het p,0.001
Range of times of rate trend change which cannot be distinguished
statistically from this changepoint**
March 2002 to January 2004
(22 months)
June 2002 to April 2003
(10 months)
September 2002 to July 2003
(10 months)
First month after April 2000 when data up to and including this
month suggest a date in this range is the most likely time for a
change in rate trend with p,0.05
July 2004 October 2003 August 2003
(p, date identified as most likely change) (p=0.005, Jan 2004) (p=0.03, Dec 2002) (p=0.03, Dec 2002)
*identified as per Methods (see Figure 1).
**based on difference in AIC of ,3.84 from the best-fitting changepoint model.
doi:10.1371/journal.pone.0002378.t002
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acquired infections, we did not study patients in the first two days
of admission, a group we have previously shown to account for
about 25% of all hospital bacteraemia in the UK[17]. Secondly,
we measured isolation from diverse specimen types, including
urine, wound and respiratory cultures. Compared with blood
stream isolates, individually, the significance of these may be more
difficult to judge. In many cases, given the clinical context and
high prevalence of MRSA as the cause of many nosocomial
infection syndromes, it is likely to reflect a nosocomial infection
with significant morbidity, mortality and cost[10–15]. In other
situations, the isolation may reflect colonisation, but given that
colonisation itself is associated with substantial risk of subsequent
infection[7–9] and that there has been a clinical indication for
taking a specimen (as opposed to a screen of an otherwise healthy
appearing individual), its inclusion in a surveillance measure may
be justified. All clinical MRSA isolations may be a good
‘‘surrogate’’ for more severe bacteraemia, with a substantial
increase in power which makes comparisons across fair smaller
geographical areas feasible.
An additional caveat is that by necessity such a surveillance
measure is restricted to clinical samples which happened to be
taken, and sampling frequency given particular conditions (such as
surgical wounds) may be determined not only by the clinical
condition but also by other factors (e.g. local policies). However,
this is probably also true of blood cultures, since indications for
blood culture are controversial in many clinical settings. We
believe these issues are largely irrelevant provided one has a goal of
determining success of infection control within an institution, if the
sampling indications remain similar over time, which is an
assumption behind much passive infectious disease surveillance.
Indeed, because of the increased frequency of our outcome
measure, we suggest our proposed measure has many advantages
over the inherently variable and infrequent bacteraemia based
outcome currently used[5].
Information provision to relevant individuals forms part of
universally recognised definitions of effective surveillance[18]. If,
as is clear, MRSA control requires action at hospital or
departmental level, ‘‘information for action’’ should be available
at these levels[18]. Our proposed measure offers an improvement
on the current situation, where the basis on which hospital-wide
actions are intensified are cross-institutional rankings heavily
determined by stochastic variation[5] and should be validated in
other hospitals.
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